Irreversible protein kinase inhibitors: balancing the benefits and risks.

Article Details

Citation
Copy to clipboard

Barf T, Kaptein A

Irreversible protein kinase inhibitors: balancing the benefits and risks.

J Med Chem. 2012 Jul 26;55(14):6243-62. doi: 10.1021/jm3003203. Epub 2012 Jun 8.

PubMed ID
22621397 [ View in PubMed
]
Abstract

Not Available

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
AfatinibEpidermal growth factor receptorIC 50 (nM)0.5N/AN/ADetails
AfatinibReceptor tyrosine-protein kinase erbB-2IC 50 (nM)14N/AN/ADetails
CanertinibEpidermal growth factor receptorIC 50 (nM)1.5N/AN/ADetails
PD-168393Epidermal growth factor receptorIC 50 (nM)0.7N/AN/ADetails
WortmanninSerine/threonine-protein kinase PLK1IC 50 (nM)24N/AN/ADetails